21.64  0.88 (4.24%)		10-15 16:00
Open: 21.04 High: 21.81 Volume: 1,093,902		Pre. Close: 20.76 Low: 20.825 Market Cap: 1,913(M)

Short term
Mid term
Targets	6-month :	30.72	1-year :	34.97
Resists	First :	26.3	Second :	29.94
Pivot price	23.14
Supports	First :	20.4	Second :	16.98
MAs	MA(5) :	21.79	MA(20) :	24.31
	MA(100) :	26.44	MA(250) :	30.23
MACD	MACD :	-1.6	Signal :	-1.3
%K %D	K(14,3) :	10.3	D(3) :	10
RSI	RSI(14): 36.2
52-week	High :	47.65	Low :	20.4

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MLYS ] has closed above bottom band by 25.9%. Bollinger Bands are 7.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	21.82 - 21.95	21.95 - 22.08
Low:	20.52 - 20.67	20.67 - 20.82
Close:	21.4 - 21.63	21.63 - 21.85

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Tue, 13 Oct 2026
An officer's proposed share sale at Mineralys Therapeutics (MLYS) lists a $78.1K market value. - Stock Titan

Tue, 13 Oct 2026
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Palvella Therapeutics (PVLA) and Mineralys Therapeutics, Inc. (MLYS) - The Globe and Mail

Tue, 13 Oct 2026
Mineralys Therapeutics, Inc. (MLYS) Stock Price, News, Quote & History - Yahoo! Finance Canada

Tue, 13 Oct 2026
Mineralys Therapeutics CEO Jon Congleton sells $1.9m MLYS stock - Investing.com

Mon, 12 Oct 2026
Mineralys Therapeutics (MLYS) Shares New Lorundrostat Data, Is The Stock A Bargain? - Yahoo Finance

Sat, 10 Oct 2026
Is Mineralys Therapeutics (MLYS) Undervalued After New Phase 3 Lorundrostat Data? - Simply Wall Street

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	88 (M)
Shares Float	67 (M)
Held by Insiders	0.6 (%)
Held by Institutions	117.5 (%)
Shares Short	7,810 (K)
Shares Short P.Month	9,330 (K)

EPS	-4.41
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	6.23
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-46.2 %
Return on Equity (ttm)	-80.9 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-4.2
Qtrly Earnings Growth	0 %
Operating Cash Flow	-139 (M)
Levered Free Cash Flow	-203 (M)

PE Ratio	-4.91
PEG Ratio	0
Price to Book value	3.46
Price to Sales	0
Price to Cash Flow	-13.79

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.